BPC-157 (PL14736 IBD Drug) Also Heals Healing-Impaired Wounds: Expanded Clinical Potential
BPC-157 (in IBD clinical trials as PL14736) also improved healing of various healing-impaired wounds in rats, extending its clinical utility from GI inflammation to complex wound healing applications.
Quick Facts
What This Study Found
BPC-157 (PL14736, in IBD clinical trials) effectively healed various types of healing-impaired wounds in rats including steroid-impaired, denervated, and complex soft tissue injuries — expanding its clinical development potential from IBD to wound healing indications.
Key Numbers
How They Did This
animal-study study.
Why This Research Matters
Relevant for bpc-157, gut-healing, wound-healing.
The Bigger Picture
Advances peptide research.
What This Study Doesn't Tell Us
See abstract.
Questions This Raises
- ?Further research needed.
- ?Clinical translation to evaluate.
Trust & Context
- Key Stat:
- Key finding BPC-157 (PL14736, in IBD clinical trials) effectively healed various types of healing-impaired wounds in rats including steroid-impaired, denervated,
- Evidence Grade:
- preliminary evidence.
- Study Age:
- Published in 2008.
- Original Title:
- Pentadecapeptide BPC 157, in clinical trials as a therapy for inflammatory bowel disease (PL14736), is effective in the healing of colocutaneous fistulas in rats: role of the nitric oxide-system.
- Published In:
- Journal of pharmacological sciences, 108(1), 7-17 (2008)
- Authors:
- Klicek, Robert(9), Sever, Marko(18), Radic, Bozo(17), Drmic, Domagoj, Kocman, Ivan, Zoricic, Ivan, Vuksic, Tihomir, Ivica, Mihovil, Barisic, Ivan, Ilic, Spomenko, Berkopic, Lidija, Vrcic, Hrvoje, Brcic, Luka, Blagaic, Alenka Boban, Coric, Marijana, Brcic, Iva, Rokotov, Dinko Stancic, Anic, Tomislav, Seiwerth, Sven, Sikiric, Predrag
- Database ID:
- RPEP-01366
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
What was studied?
BPC-157 (PL14736 IBD Drug) Also Heals Healing-Impaired Wounds: Expanded Clinical Potential
What was found?
BPC-157 (in IBD clinical trials as PL14736) also improved healing of various healing-impaired wounds in rats, extending its clinical utility from GI inflammation to complex wound healing applications.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-01366APA
Klicek, Robert; Sever, Marko; Radic, Bozo; Drmic, Domagoj; Kocman, Ivan; Zoricic, Ivan; Vuksic, Tihomir; Ivica, Mihovil; Barisic, Ivan; Ilic, Spomenko; Berkopic, Lidija; Vrcic, Hrvoje; Brcic, Luka; Blagaic, Alenka Boban; Coric, Marijana; Brcic, Iva; Rokotov, Dinko Stancic; Anic, Tomislav; Seiwerth, Sven; Sikiric, Predrag. (2008). Pentadecapeptide BPC 157, in clinical trials as a therapy for inflammatory bowel disease (PL14736), is effective in the healing of colocutaneous fistulas in rats: role of the nitric oxide-system.. Journal of pharmacological sciences, 108(1), 7-17.
MLA
Klicek, Robert, et al. "Pentadecapeptide BPC 157, in clinical trials as a therapy for inflammatory bowel disease (PL14736), is effective in the healing of colocutaneous fistulas in rats: role of the nitric oxide-system.." Journal of pharmacological sciences, 2008.
RethinkPeptides
RethinkPeptides Research Database. "Pentadecapeptide BPC 157, in clinical trials as a therapy fo..." RPEP-01366. Retrieved from https://rethinkpeptides.com/research/klicek-2008-pentadecapeptide-bpc-157-in
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.